



Barry Robson, PhD, D.Sc., Professor Emeritus Epidemiology Biostatistics and Evidence Based Medicine, Fellow of the Royal Society of Medicine, was for 6 Years at the T. J. Watson Research Center as the Strategic Advisor to

IBM Research and for 5 years Chief Scientific Officer IBM Global Healthcare Pharmaceutical and Life Sciences. At IBM he also carried out research in high dimensional data mining, prediction, and risk assessment in medicine and financial markets. He did his PhD in medical biochemistry and protein biophysics, and his DSc (a higher UK doctorate) in computational and quantum chemistry, and molecular design. According to a two-page biography by journalist Brendan Horton in *Nature* (389,418-420, 1997), Barry was a pioneer in bioinformatics, protein modeling, and computer-aided drug design. Barry's current main interests are in quantification of risk in Decision Support and Expert Systems, probabilistic semantics and ontology languages, AI including with reference to neuroscience and quantum computing, public health and socioeconomic analytics, and applications of bioinformatics, as well as prediction and risk assessment, to emerging epidemics.

Barry was the scientific founder and Research Director at Proteus International plc, ultimately part of Boston Scientific via BTG plc, and CSO Gryphon Sciences partly owned and later acquired by SKB. He was also Principal Scientist MDL Information Systems where he co-led development of the combined bioinformatics and storage system to help produce the first draft of the human genome. He has also held professorial positions in four major universities and was a Visiting Scholar at Stanford University School of Medicine for two years. He has over 350 publications and patents, a 700-page Elsevier textbook on proteins and protein engineering, and a 600-page Wiley book on medical IT and AI. Currently, he is cofounder of Ingene Inc., Cleveland, Ohio, and CEO of the Dirac Foundation, Oxfordshire, UK, a stakeholder to the NICE that provides the guidelines for the UK's NHS. He serves on the editorial boards of two Elsevier journals. Barry's honors include titles of IBM Distinguished Engineer and Distinguished Scientist at the University of Wisconsin-Stout, the Asclepius Award for Outstanding Vision in Health Technology, Future of Health Technology Congress, M.I.T. in 2001 (in the presence of the first recipient Marvin Minsky, considered the father of AI), the first IBM Award in Clinical Genomics in 2005, and a press release from the American Chemical Society for a paper regarding a secure Genomic Messaging System. He has published several reports to several European government bodies and was contributor to National Innovation Initiative "Innovate America" Published by The Council On Competitiveness, Washington D.C. He has recently worked with several US and UK companies and government-linked organizations in relation to guidelines for physicians and health IT systems. He led teams which produced the first diagnostic and vaccine design response to AIDS, the BSE diagnostic marketed worldwide by Abbott Laboratories, and is recognized as a very early responder to research on the Wuhan Seafood Market isolate, later known as the Covid-19 virus, in January 2020.